SCOTTSDALE, Ariz.–(BUSINESS WIRE)–PHIL, the technology-powered patient access platform, today announced the launch of New Day™ Direct-to-Patient program in partnership with Evolved Health. The program delivers a first-of-its-kind prescription topical emulsion spray for mild to severe atopic dermatitis directly to patients.
New Day™ Skin Spray is powered by peptide technology from Evolved By Nature, which was further developed into a medical device by the team at Evolved Health. New Day™ Skin Spray can be used as a monotherapy or adjunctive therapy, and is now available to prescribe in select markets, with broader national rollout planned to follow. Combining Evolved Health’s novel therapy and PHIL’s innovative platform, the companies have teamed up to build a custom access program to help atopic dermatitis patients access treatment quickly and affordably.
Bringing Affordable Access to Atopic Dermatitis Patients
Atopic dermatitis affects an estimated 19.8 million adults and 9.2 million children in the United States. One study found that over 40% of people diagnosed with atopic dermatitis pay over $1000 USD out-of-pocket costs for treatment annually, a significant financial burden for many patients and families.
Atopic dermatitis can present itself differently in a three-month-old, a teenager, or an eighty-year-old, and each case has traditionally carried its own set of precautions and exclusions. New Day™ Skin Spray was built to remove these restrictions.
The opportunity to help patients living with atopic dermatitis improve their quality of life with more affordable, accessible care is significant, and is the guiding purpose behind the Evolved Health and PHIL partnership.
“New Day™ Skin Spray was designed to be easy for patients, with no burdensome protocols, no washout periods, and no systemic exposure. That’s a unique label for a prescription therapy, but we had the technology and safety profile to support it. We wanted our access strategy to be as easy and impactful as the product, and PHIL understood our vision from first conversation. We’re excited to launch this direct-to-patient program with their support and partnership.” – Rebecca Lacouture, President, Evolved Health
An Innovative Program for a Novel Therapy
Evolved Health and PHIL partnered to co-design the New Day™ Skin Spray Direct-to-Patient program from the ground up to build the quickest, most affordable path to treatment for patients. If prescribed New Day™ Skin Spray, patients submit their insurance information during intake and pay a $15 copay, no prior authorization or step therapy required. New Day™ Skin Spray ships directly to patients for free in 3-5 days, ensuring patients get the quick relief they need, with ongoing adherence support and built-in education to support better treatment outcomes.
“We are thrilled to partner with Evolved Health on the launch of New Day™ Skin Spray, helping support the millions of patients managing atopic dermatitis with affordable access to a one-of-a-kind treatment. Evolved Health has brought a unique approach to dermatology, and we feel honored to bring our shared vision for better patient access to life through the New Day™ program.” – Josh Zeidman, SVP Business Development, PHIL
About Evolved Health
Evolved Health develops and commercializes prescription medical device applications. New Day™ Skin Spray is its first commercial product, developed from Evolved By Nature’s peptide technology. Prescribing information and patient access details are available at NewDaySkinSpray.com or through the New Day™ Skin Spray team at [email protected].
About PHIL Inc.
PHIL is a healthcare technology company that helps pharmaceutical brands empower patients with affordable access to their prescribed medications. Through our digital hub and direct-to-patient platform, PHIL supports access, affordability, and adherence at scale. For more information, visit phil.us.
Contacts
Media contact:
Mirah Gocher, [email protected], PHIL Inc.
